EFB Dengue Literature Review

TLR7

27 min read

TLR7

Overview

TLR7 (Toll-like Receptor 7) is an endosomal pattern recognition receptor that senses single-stranded RNA (ssRNA). In B cells, TLR7 signalling triggers activation, proliferation, and — in the presence of appropriate cytokines — plasma cell differentiation. TLR7 is of central pathogenic significance in SLE, where endogenous RNA (from immune complexes containing Sm/RNP autoantigens) provides chronic TLR7 stimulation. In acute viral infections including dengue, exogenous viral ssRNA is the physiological TLR7 ligand.

Key Points from Literature

  • DN2/aNAV hyper-responsiveness to TLR7: R848 (TLR7/8 agonist) strongly induces CD25 expression and pERK/pMAPKp38 phosphorylation in DN2 and aNAV cells but not in SWM, DN1, or NAV. TLR7 also upregulates HLA-DR and CD86 in DN2 cells while downregulating inhibitory receptors CD72 and CD32b (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, phospho-flow n=5–10).

  • TLR7 as required signal for EF differentiation: In vitro, TLR7 (R848) is essential for rNAV → aNAV → DN2 → PC differentiation. Removing R848 results in >95% cell death by day 7 and drastically reduced PC frequencies. Specific TLR7 inhibition with ODN 20959 produces the same effect (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • TLR7 overexpression in SLE B cells: SLE B cell transcriptomes are enriched for viral RNA sensors including TLR7 and IFIH1, plus the downstream kinase TBK1. This constitutes an overexpression of the pathway that drives DN2 activation (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, RNA-seq).

  • TLR7 + IL-21 + IFN-γ = minimal signal for DN2 → PC: DN2 cells differentiate into PC through signal 3 alone (TLR7 + IL-21 + IFN-γ) without BCR stimulation or CD40L, and without extensive cell division (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • TLR7 gain-of-function mutations cause human SLE: Monogenic TLR7 GoF mutations result in human SLE with elevated ABC/DN2 cells. In mice, the orthologous TLR7 mutation induces lupus in a B cell-intrinsic, GC-independent fashion — ABC expansion and pathology proceed without GC involvement (see Sanz2025 - Human Atypical B Cells Overview, review citing Brown et al. 2022).

  • TLR7 plays an obligatory role in DN2 differentiation: TLR7 is required for both the initial activation of naive B cells into DN2 and for DN2 differentiation into ASC (see Sanz2025 - Human Atypical B Cells Overview, review citing Zumaquero et al. 2019).

  • Enhanced TLR7 activity through indirect mutations: Mutations enhancing endosomal TLR activity drive ABC/DN2 expansion and autoimmunity: NOX2 deficiency (NCF1/NCF2 loss-of-function) fails to terminate endosomal TLR signalling; UNC93B1 instability increases TLR7 activity. These defects break tolerance in a B cell-intrinsic fashion (see Sanz2025 - Human Atypical B Cells Overview, review).

  • SLE is enriched in all TLR7 pathway components: High TLR7 copy numbers and activity, elevated IFN-γ and IL-21 serum levels, high abundance of TLR7 ligands (including XIST lncRNA), and defective X chromosome inactivation all converge to amplify TLR7 signalling in SLE B cells (see Sanz2025 - Human Atypical B Cells Overview, review).

  • CD21lo cells have increased TLR7 sensitivity: CD21lo B cells show increased TLR7 sensitivity, which could contribute to their recruitment into the ABC compartment and SLE expansion (see Sanz2025 - Human Atypical B Cells Overview, review citing Zhu et al. 2024).

  • TLR7 inhibition as therapeutic strategy: Small molecule TLR7/8 inhibition (ENPATORAN) showed promising results in the phase II Willow study in cutaneous lupus. Targeted TLR7 inhibitor delivery via nanoparticles is also being explored (see Sanz2025 - Human Atypical B Cells Overview, review).

  • Dengue relevance: Dengue virus is an ssRNA flavivirus; during viraemia, TLR7 ligands are physiologically abundant. Whether the TLR7-driven EF differentiation programme operates during acute dengue — potentially driving the massive plasmablast expansion at days 7–10 — is a key open question.

  • TLR9 as mechanistic precedent for TLR-driven EF SHM (murine). In the foundational EF SHM study (William2002), the authors propose that TLR co-stimulation is a unifying feature of dominant autoantigens, citing Leadbetter et al. (2002) showing chromatin-containing immune complexes co-stimulate RF B cells via TLR9. TLR9 (DNA-sensing) and TLR7 (ssRNA-sensing) are structurally and functionally related endosomal TLRs that share the MyD88 signalling adaptor. The TLR9-driven EF pathway in the murine RF system is the direct precursor to the TLR7-driven human DN2 pathway described by Jenks2018 — different TLRs sensing different ligands but driving analogous outcomes of sustained B cell proliferation, SHM, and autoantibody production outside GCs (see William2002 - Extrafollicular Somatic Hypermutation in Autoimmune Mice, citing Leadbetter et al. 2002, Nature).

  • Proposed mechanism for T-independent CSR in dengue via TLR7: GodoyLozano2016 explicitly proposes that endosomal DENV recognition by TLR7 provides a synergic signal with the BCR for T-independent class switch recombination, producing IgG-switched but poorly mutated antibodies. In mice, TLR7 and TLR9 synergise with BCR signalling to promote AID expression (required for both CSR and SHM); T-independent IgG responses against Polyomavirus require MyD88 (the canonical TLR adaptor). This provides a mechanistic link between the abundant TLR7 ligand (DENV ssRNA during viraemia) and the paradoxically low-SHM IgG observed in acute dengue — CSR is induced via TLR7+BCR but without the iterative SHM cycling of GC reactions (see GodoyLozano2016 - Lower IgG SHM Rates in Acute Dengue, proposed model, citing Pone et al. 2012 and Raval et al. 2013).

  • Endosomal TLR7 and TLR9 together drive the ABC/atypical phenotype. ABCs are hyper-responsive to both endosomal TLR7 and TLR9 and are driven to differentiate by TLR stimulation in combination with IFN-γ and/or IL-21 (IFN-γ → T-bet, IL-21 → CD11c). BCR signalling contributes (with CD40) but cannot drive differentiation alone (see Lamprinou2026 - ABCs and DN B Cells, opinion, citing Cancro 2020 / Rubtsov 2011 / Naradikian 2016 / Liu 2024 / Imabayashi 2025; Age-Associated B Cell).

  • TLR7 is X-linked — a proposed basis for the female autoimmunity bias. Because TLR7 is encoded on the X chromosome and is closely tied to ABC activation, its gene dosage is offered as a partial explanation for the higher incidence of autoimmunity in females (see Lamprinou2026 - ABCs and DN B Cells, opinion, citing Sachinidis 2020). This complements the wiki’s existing Sanz2025 evidence (XIST ligand, defective X-inactivation) converging on amplified TLR7 signalling in female SLE.

  • Endosomal TLR signalling is a stated requirement for ABC differentiation. ABCs arise following BCR stimulation in an inflammatory cytokine milieu, “with their differentiation requiring additional signals from endosomal TLRs, as well as from IFN-γ and IL-21” (see Glaros2025 - Multilayered Identity of B Cell Memory, review, no original data). The review generalizes to endosomal TLRs rather than naming TLR7 specifically — consistent with the wiki’s TLR9 precedent from William2002 - Extrafollicular Somatic Hypermutation in Autoimmune Mice and the TLR7 pathway from Jenks2018 - DN2 B Cells and EF Pathway in SLE.

  • But TLR/inflammatory signals alone are not sufficient — antigen and T cell help are also required. The review is explicit that ABCs are “not merely byproducts of inflammation”: ABC frequencies fall significantly in patients with CD40/CD40L mutations, and ABCs do not develop in mice with fixed BCR specificity under steady-state conditions. Chronic BCR signalling converts anergic B cells into ABCs (citing Imabayashi 2025 Sci Adv). This qualifies any purely innate-driven reading of the TLR7→DN2 axis: TLR7 is a required co-signal, not a standalone driver of the in vivo population.

  • TLR7/TLR9 poising is necessary but not sufficient for ABC fate — must be followed by IFN-γ or IL-21. Endosomal TLR7 or TLR9 signalling poises a naive B cell for the ABC fate, but poising alone is not sufficient: it must be followed by IFN-γ or IL-21. Neither BCR ligation alone nor BCR ligation with CD40 costimulation enables ABC fate, though BCR does synergise with TLR signalling for proliferation. Coculture experiments established that both the TLR and the cytokine requisites are cell-intrinsic (see Cancro2020 - Age-Associated B Cells, review — no original data; mouse, in vitro + in vivo). This sharpens the wiki’s existing TLR7-centric framing from Jenks2018 - DN2 B Cells and EF Pathway in SLE and Glaros2025 - Multilayered Identity of B Cell Memory into an explicit two-signal model with TLR9 as an alternative first signal to TLR7.

  • ABCs proliferate robustly to TLR7/TLR9 while remaining largely BCR-refractory. ABCs do not divide in response to BCR cross-linking alone (unlike FO B cells) but remain viable (unlike MZ and transitional B cells, which die rapidly under the same conditions); they proliferate strongly to TLR7 or TLR9 ligands, and BCR cross-linking synergises with TLR signalling for additional rounds of division rather than acting alone. HIV “tissue-like memory” B cells show the identical pattern — BCR-hyporesponsive, TLR9-responsive — reinforcing the cross-species generality of this signature (see Cancro2020 - Age-Associated B Cells, review — no original data; mouse + human, functional assay).

  • ★ TLR7 and TLR9 act in OPPOSITE directions on autoimmunity — TLR9 is a tolerance checkpoint, not merely a redundant activator. TLR7 gene-dose duplications foster autoimmune disease and TLR7 deficiency ameliorates it, but TLR9 knockouts exacerbate autoimmune manifestations — earlier disease onset, more severe glomerulonephritis — indicating TLR9 normally helps maintain peripheral B cell tolerance rather than simply drive ABC pathology alongside TLR7 (see Cancro2020 - Age-Associated B Cells, review — no original data; mouse, knockout). This qualifies every TLR7-only framing elsewhere on this page and on Extrafollicular Response — TLR9 is not interchangeable with TLR7 in its net effect on autoimmunity even though both can poise the ABC fate.

  • The TLR9-tolerance mechanism (Sindhava et al. 2017): BCR-delivered TLR9 ligand triggers programmed death, rescuable into the ABC fate. B cells stimulated with antigen that delivers a TLR9 ligand via the BCR undergo cell-cycle arrest and mitochondrial cell death after an initial proliferative burst. This programmed death is circumvented by survival cytokines or CD40 costimulation — and critically, in the presence of IFN-γ or IL-21 the rescued cells assume the ABC phenotype. The interpretation: the ABC–autoimmunity association may reflect failure of, or rescue from, this tolerance mechanism, and more broadly that pattern-recognition parsing of internalised antigen components — not BCR epitope specificity per se — underlies peripheral B cell tolerance (Sindhava et al. 2017, J Clin Invest, cited in Cancro2020 - Age-Associated B Cells, review — no original data; mouse). This is a candidate mechanism for the bridge-wiki/ cells→autoantibody arm that does not require a soluble self-antigen route — see the source page’s Questions Raised.

  • R848 acts at both ends of the differentiation sequence — early for survival, late for proliferation. Using a two-step culture (days 0–3 / days 3–6) with the defined cocktail anti-Ig + IFN-γ + IL-2 + IL-21 + BAFF + R848, early TLR7/8 signal supported B cell survival while late TLR7/8 signal drove proliferation. The resulting model is B_N →(anti-Ig, R848, IFN-γ)→ pre-ASC (T-bet^hi^IRF4^int^) →(R848, IL-21)→ ASC (T-bet^lo^IRF4^hi^) (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, human in vitro, healthy-donor reconstruction + sorted SLE subsets). This is the first ingested source to give the TLR7 requirement a temporal structure rather than a single on/off role.

  • ★ TLR7/8 is dispensable for making the pre-ASC, but obligate for making the ASC — the requirement is stage-specific. In day-3 “all minus one” cultures, omitting R848 — or anti-Ig, IL-21, BAFF or IL-2 — gave results similar to the complete cocktail: essentially all naive B cells still upregulated T-bet and IRF4. Only omission of IFN-γ broke it (>80% of cells left T-bet^neg/lo^, and they also failed to upregulate IRF4), which is what makes IFN-γ obligate for generating the T-bet^hi^IRF4^int^ pre-ASC population. Across the full 6 days, however, ASC recovery in cultures lacking R848 was at background — as it was without IFN-γ — and no ASCs at all formed without IL-21, while BAFF and IL-2 reduced ASC numbers without being obligate. So: IFN-γ builds the pre-ASC; TLR7/8 and IL-21 are what convert it into an antibody-secreting cell (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, human in vitro, healthy-donor reconstruction). Separately and on a different readout, >95% of naive B cells activated with the full cocktail resembled SLE DN2 cells by day 6 — IgD⁻CD27⁻T-bet^hi^IRF4^int^, CD11c⁺FcRL5⁺, losing CD21 and CXCR5. ⚠ Do not pair that 95% against any day-3 induction figure; they measure different things.

  • ★ IFN-γ synergises with subthreshold TLR7/8 — a 100-fold dose effect. At high-dose R848 (10 µg/ml) cells proliferated regardless of IFN-γ; at a 100-fold lower dose (0.1 µg/ml) proliferation occurred only when IFN-γ was present, and ASC frequency was ~10-fold higher with IFN-γ. The quantity of TLR7 ligand needed to run the DN2 programme is therefore set by the cytokine milieu, not fixed — which matters for transferring the mechanism into infection, where ssRNA burden varies over orders of magnitude across the viraemic window (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, human in vitro). Downstream, NF-κB p65 and REL motifs — the transcription factors shared by BCR and TLR7/8 signalling — were most accessible in the combined condition.

  • TLR7 and TLR9 are predicted as upstream regulators even when no TLR ligand is supplied. Ingenuity Pathway Analysis of the Be1-versus-Be2 differentially expressed gene set returned TLR7 and TLR9 among predicted upstream regulators despite neither ligand being added to those cultures, which the authors attribute to endogenous ligands released by dying cells (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, human in vitro). Relevant to dengue, where cell death is abundant during the acute phase — endogenous ligand may supplement viral ssRNA.

  • ★ Germline TLR7 variation does not stratify dengue clinical form. In 165 adult dengue patients (DF n=100, DHF n=65) plus 89 general-population controls from Veracruz, Mexico, the two TLR7 SNPs genotyped — rs179008 (exonic, A/T, Gln11Leu) and rs3853839 (3′-UTR, C/G) — showed no statistical association in the crude analysis with DF, with DHF, or with dengue versus controls. The study’s only positive genetic signal was in TLR4, and it separated dengue from controls rather than DF from DHF (see Posadas-Mondragon2020 - TLR Polymorphisms and Clinical Forms of Dengue, n=254 case-control, WHO 1997 criteria, DENV-2-dominant, acute phase 1–8 d). See Contradictions & Debates below before reading this as evidence against the TLR7 mechanism — it is not.

  • TLR7’s X-linkage forces a sex-split analysis, and that is where the power goes. Because TLR7 is X-encoded, all analyses in that cohort were run separately for men and women — methodologically obligatory, and also the reason the study could not answer the question: DHF women numbered 28 before any covariate stratification (see Posadas-Mondragon2020 - TLR Polymorphisms and Clinical Forms of Dengue). This is the practical cost of the same X-linkage that Lamprinou2026 - ABCs and DN B Cells and Sanz2025 - Human Atypical B Cells Overview invoke as a mechanism for the female bias in ABC expansion, and it sets a design constraint: any future study seeking an X-linked TLR7 effect in dengue must be powered for the sex-split at the outset.

  • ⚠ Exploratory TLR7 × antibody / monocyte interactions exist in that paper but are not usable — pointer only. The same study cross-tabulated TLR7 genotype against tertile-split total IgG, IgG1, IgG3 and monocyte levels, reporting directional associations mostly in DHF women. Those results are unadjusted for multiplicity, rest on single-digit strata, are reported only as forest plots with no readable odds ratios or confidence intervals, and are internally inconsistent between Results and Discussion on whether one finding is women-only — and rs3853839, the SNP the Discussion leans on, deviates from Hardy–Weinberg equilibrium in the case group. Detail is confined to Posadas-Mondragon2020 - TLR Polymorphisms and Clinical Forms of Dengue by curator decision [2026-08-23] and is deliberately not synthesised onto this page.

  • ★ Dengue virus engages human TLR7 — the wiki’s first primary demonstration, not an inference. In human Plasmacytoid Dendritic Cells, IFN-α induced by live dengue-2 virus was significantly reduced by the TLR7 antagonist IRS 661 (2.8 µM) relative to no inhibitor or a control ODN, p < 0.02 (see Wang2006 - Flavivirus Activation of pDCs and TLR7 Signaling, in vitro, n=4 independent experiments, pDCs >85% pure). Heat inactivation at 56 °C abolished the response, and transmission EM placed enveloped D2V particles inside endocytic vacuoles within 5 min of warming. Until this source, this page’s line that “during viraemia, TLR7 ligands are physiologically abundant” was an inference from virology; the closest prior evidence was Kwissa2014 - Monocytes Drive Plasmablast Differentiation in Dengue, where R-848 mimicked DENV’s monocyte conversion rather than DENV being blocked at the receptor. ⚠ The cell is a pDC. No ingested source has measured TLR7 responsiveness in human B cells during dengue — that gap is unchanged, and arguably sharpened: the ligand and the sensor are demonstrably meeting in two myeloid/dendritic cell types and nobody has looked at the B cell.

  • ⚠ Attribution rests on an inhibitory ODN, not a human knockout. IRS 661’s TLR7 antagonism was validated by the same authors on purified mouse TLR7⁻/⁻ and TLR9⁻/⁻ pDCs; the human experiments used the inhibitor alone. CpG 2336 appears in the same figure as a TLR9 comparator, but the text does not state it was unaffected by IRS 661, so no TLR9 negative should be read from it (see Wang2006 - Flavivirus Activation of pDCs and TLR7 Signaling).

  • ★ Genomic viral RNA outclasses synthetic ssRNA at TLR7 by 50–1000×. Transfected into pDCs (n=6 independent experiments), influenza and dengue-2 genomic vRNAs were 50–100× more potent than siRNA 9.2 and 100–1000× more potent than ssRNA40; influenza vRNA gave 1.5–3× higher peak IFN-α than dengue-2 vRNA, and both exceeded in-vitro-transcribed Sin Nombre G2 RNA by ≥10×. In a TLR Reporter Cell Assay, siRNA 9.2 and ssRNA40 induced nothing at all — no NF-κB, no IL-8, no type I IFN — across 0.02–2000 nM (see Wang2006 - Flavivirus Activation of pDCs and TLR7 Signaling, in vitro). The implication for this wiki is set out under Contradictions & Debates: SLE’s endogenous ligands and acute dengue’s viral genome are not the same potency class.

  • ★ Shape, not length or 5′ chemistry, sets TLR7 potency. Potency was not strictly length dependent — influenza segments (0.8–2 kb) beat the 11-kb dengue-2 genome. UV cross-linking, which alters tertiary structure, cut dengue-2 vRNA signalling to 23% of untreated in HEK/hTLR7 and 40 ± 15% in pDCs, while influenza vRNA fell only to 92% and 76 ± 2% respectively (n=2, directional). Structural negatives are equally informative: synthetic influenza 5′ conserved end (16 nt), 3′ conserved end (14 nt) and the 49-nt panhandle produced no signalling; proteinase K and Triton X-100 had no effect; and removing 5′- and γ-phosphates with tobacco acid pyrophosphatase had no effect (see Wang2006 - Flavivirus Activation of pDCs and TLR7 Signaling, in vitro). The authors propose the same logic explains why nucleoside-modified mammalian RNA fails to activate TLR7/8 — modifications acting through higher-order structure rather than by direct recognition.

  • TLR7 activation is linked to virus fusion/uncoating, not merely to endosomal arrival. Chloroquine (3.2 µM), raising mean intraendosomal pH 4.5 → 5.2, blocked influenza but not dengue or R-848; bafilomycin A1 (20 nM), raising it to 5.8, blocked both viruses. This matches the two viruses’ different fusion biology — influenza fuses in late endosomes at lower pH (type I fusion), flaviviruses in early endosomes (type II) — so TLR7 activation tracks the fusion/uncoating step and can occur at more than one acidic pH (see Wang2006 - Flavivirus Activation of pDCs and TLR7 Signaling, in vitro). The authors are candid that no current fusion model explains how vRNA reaches the intraendosomal space, and that “leakage across the viral membrane during fusion and uncoating is likely an oversimplification.”

  • The TLR7→type I IFN arm has a higher activation threshold than the TLR7→NF-κB→IL-8 arm — and the threshold is cell-dependent. In HEK/hTLR7, ligands formed a stepwise series: short synthetic RNAs (nothing) → R-848 and poly(U) (NF-κB/IL-8 only) → genomic vRNAs (both arms). The authors model type I IFN output as proportional to [(limiting molecule) × (agonist)]²/K_d, implying receptor multimerization, consistent with transfected influenza vRNA giving an inverted-U dose response in HEK/hTLR7 but a log-linear one in pDCs (see Wang2006 - Flavivirus Activation of pDCs and TLR7 Signaling, in vitro). ⚠ See Contradictions & Debates before applying the reporter-line branch result to R-848 anywhere in this wiki.

  • TLR7 stimulation raises activation markers on DN2 specifically — hyper-responsiveness beyond the phospho-flow readout. R848 increased CD25, HLA-DR and CD86 on DN2 cells, on top of the enhanced pERK/pMAPKp38 already recorded on this page. The hyper-responsive phenotype is therefore visible in surface activation state, not only in proximal signalling (see Beckers2023 - Origins and Functions of DN B Cells, review, citing Jenks 2018).

  • ⚠ TLR7 also drives ASC differentiation from DN1 — the cocktail is not DN2-selective. GC-dependent DN1 cells differentiate into ASCs in vitro under the same TLR7 + BCR ligation + IFN-γ + IL-21 stimulation used for DN2. The review states explicitly that “it is not yet clear whether this ASC differentiation by DN1 cells is dependent on TLR7 or BCR signaling.” TLR7 responsiveness should therefore not be treated as a property that distinguishes DN2 from DN1 in functional assays, only in magnitude of proximal signalling (see Beckers2023 - Origins and Functions of DN B Cells, review, citing Jenks 2018).

  • Activated naive B cells are TLR7-responsive alongside DN2, and convert to DN2 under TLR7 + IFN-γ + IL-21. This is the review’s central evidence for a GC-independent origin of DN2/DN3 (see Beckers2023 - Origins and Functions of DN B Cells, review, citing Jenks 2018; see Activated Naive B Cell).

  • A parallel TLR9 literature reaches no such consensus. Where TLR7 responsiveness of DN2 is consistent across studies, DN proliferation to the TLR9 ligand CpG is reported four different ways by four groups. The asymmetry is itself informative: the TLR7 result rests on signalling and differentiation readouts in sorted subsets, the TLR9 results on bulk-DN proliferation assays with differing markers and donor ages (see Beckers2023 - Origins and Functions of DN B Cells, review; see TLR9).

  • ★ TLR7 ligands drive GC and GC-independent responses — TLR9 is the one that drives the GC-independent arm selectively. This distinction matters because the wiki has treated endosomal ssRNA sensing as the EF-biasing signal. The consensus Perspective’s synthesis (Box 2) separates them: antigens that strongly crosslink TLR9 and the BCR potently drive EF responses, whereas antigens containing TLR7 ligands induce both robust GC and EF antibody responses — a pattern described as commonly observed in lupus-prone mice, and consistent with monogenic TLR7 gain-of-function driving GC, plasma cell, and autoantibody production. TLR7 signalling is therefore better described as amplifying B cell responses in a type-1 direction than as switching the pathway. For dengue, whose genomic ssRNA is the potent TLR7 ligand class (see Wang2006 - Flavivirus Activation of pDCs and TLR7 Signaling), this predicts a concurrent GC and GC-independent response rather than GC displacement (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data).

  • IL-4 suppresses TLR7’s ability to drive the GC-independent pathway, while IL-4 and IL-13 support B cell migration into the follicle to form GCs; IL-12 and IFN-γ favour the GC-independent arm. B cell-intrinsic MyD88 and TRIF were both required for strong plasmablast accumulation in lymph nodes after influenza A infection, acting via enhanced NF-κB c-Rel nuclear translocation, which induces IRF4 — a route linking TLR engagement to ASC commitment that is independent of the IL-21/STAT3 axis the wiki has emphasised (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data).

  • ★ The review’s framing is that the TLR7 programme is a state accessible to many populations, not a lineage. Its unifying statement: “ABC-like cells represent activated effector B cells induced by TLR7 and driven by IL-21 and IFN produced by TFH cells in Th1-type responses within multiple and possibly, all B cell populations.” The supporting observation is that in vitro stimulation of naive, DN and memory starting populations under mouse-ABC-inducing conditions (TLR7, IFN, IL-21) all converge on CD19++CD21ˡᵒCD11c++T-bet++FcRL5⁺ — which is why the same review then argues that CD21, T-bet or CD11c cannot identify a distinct population (see Sanz2019 - Consistent Classification of Human B Cell Populations, review — no original data). See Atypical B Cell, CD11c.

  • ★ Sustained TLR7 ligation suppresses antibody-secreting cell formation — a direction opposite to TLR7’s DN2-generating role. Adding TLR7 (R848) or TLR9 (CpG ODN1826) ligands to wild-type mouse Be1 cultures from day 2 significantly reduced CD138⁺CD93⁺ ASC and IgG-secreting cell numbers, reproducing the defect seen when T-bet is deleted. This was not a proliferation artefact — cells expanded equally well in TLR7 and TLR9 ligand conditions (see Stone2019 - T-bet Promotes ASC Differentiation by Limiting IFN-gamma Inflammation, mouse, in vitro, ≥2 independent experiments). The mechanistic reading is that TLR-driven NF-κB activity sustains an inflammatory effector state incompatible with terminal differentiation, and that one of T-bet’s jobs is to downmodulate it. This sits in unresolved tension with the TLR7-driven DN2 generation model the wiki carries from SLE — see DN2 B Cell Key Points for the timing problem it creates.

Contradictions & Debates

★ The SLE and dengue TLR7 ligands are different potency classes — and this cuts in dengue’s favour. Wang2006 - Flavivirus Activation of pDCs and TLR7 Signaling places short synthetic ssRNAs 50–1000× below genomic viral RNA, shows conserved-end and panhandle motifs do nothing at all, and identifies higher-order shape as the determinant. The endogenous TLR7 ligands invoked throughout the SLE literature on this page — RNP-associated small RNAs from immune complexes — sit in the weak class. Acute dengue supplies an intact, structured 11-kb genome — the potent class. If the DN2 programme is TLR7-signal-strength-dependent (and Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation’s 100-fold R-848 dose experiment says signal strength is exactly what sets the cytokine requirement), then transferring the SLE-derived model to dengue is not obviously a stretch toward a weaker stimulus. It may be a stretch toward a stronger one. This is a wiki-generated inference across two sources, flagged as such, and it is testable.

Held in tension with it, deliberately unresolved: per infectious unit, dengue is the weaker pDC stimulus — ~50× the MOI of influenza for the same order of IFN-α — and its potency collapses on UV inactivation (2.6 ± 0.9% of live, versus influenza’s 65.2 ± 10.5%). The resolution the wiki adopts is that live-virus potency is gated by fusion/uncoating delivery and genome structure, not by intrinsic ligand quality: as purified RNA, dengue’s genome sits in the top potency class. The unexamined question is which of those two regimes a B cell encountering immune-complexed DENV is actually in. Note also that only DENV-2 was tested — if tertiary structure sets potency, the four serotypes need not be equivalent TLR7 agonists.

⚠ Do not read the reporter-line result as “R-848 does not engage the type I IFN branch.” In Wang2006 - Flavivirus Activation of pDCs and TLR7 Signaling’s HEK/hTLR7 line, R-848 drove NF-κB and IL-8 but no type I IFN. In primary pDCs the same agonist produced 13,694–18,381 pg/ml IFN-α, and the paper says so explicitly, attributing the difference to pDCs’ higher levels of limiting pathway components (IRF-7 named). The reporter-line negative is a property of the reporter line. Nothing on this page is qualified by it: the wiki’s DN2 evidence reads proliferation, T-bet/IRF4 induction and ASC yield out of R-848 on B cells and never claims a B-cell type I IFN output. What the result does add is narrower and real — R-848 is a low-potency (high-K_d) TLR7 agonist relative to genomic viral ssRNA, and its dose–response cannot be extrapolated across cell types. B cell IRF7 and limiting-component abundance is untouched by any ingested source. Recorded because the opposite reading is an easy and consequential error.

★ Functionally obligate in vitro, genetically null in vivo — and these are compatible. Nearly every bullet above treats TLR7 as required for DN2 generation and for DN2 → ASC differentiation. That evidence is human, in vitro, and overwhelmingly SLE-derived (Jenks2018 - DN2 B Cells and EF Pathway in SLE, Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation). Set against it, Posadas-Mondragon2020 - TLR Polymorphisms and Clinical Forms of Dengue finds that germline TLR7 variation does not stratify dengue clinical form (n=254 case-control). The two are not in conflict. A candidate-gene study asks whether inherited variation in a gene stratifies outcome; the in vitro work asks whether the pathway is used. An essential pathway is under purifying selection, so the common variation that persists in a population is by construction variation that does not break it — a null association is the expected result for an essential gene, not a refutation of it.

Two symmetric misreadings to guard against. (a) Reading the null as evidence that TLR7 is unimportant in dengue. It is not evidence of that, and no ingested source has measured TLR7 responsiveness in human B cells during dengue at all — the closest is Kwissa2014 - Monocytes Drive Plasmablast Differentiation in Dengue, which is TLR7/8 signalling in monocytes. (b) Reading the same paper’s §3.8 interaction analysis as support for a TLR7 role in dengue. It is unadjusted, multiplicity-uncontrolled and numberless, and cannot support anything. The wiki’s position is that this axis remains untested in dengue in either direction.

⚠ Wiki-generated caveat: “TLR7” on this page frequently means “TLR7/8”. The dominant reagent across Jenks2018 - DN2 B Cells and EF Pathway in SLE and Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation is R848 (resiquimod), a dual TLR7/8 agonist, and Kwissa2014 - Monocytes Drive Plasmablast Differentiation in Dengue’s monocyte-conversion experiment used R-848 likewise. Where a bullet’s evidence is R848-based it strictly demonstrates endosomal ssRNA-sensor dependence, not TLR7 specificity. Two ingested results do isolate TLR7: Jenks2018’s TLR7-specific inhibitor ODN 20959 reproduced the R848-withdrawal phenotype, and Sanz2025 - Human Atypical B Cells Overview reports monogenic TLR7 gain-of-function causing human SLE. Beyond those, TLR8 is not formally excluded anywhere in the wiki and has no entity page. Flagged 2026-08-23; this is a wiki-generated observation, not a claim made by any source.

Reinforced 2026-08-23: reagent datasheet labels are not receptor-specificity claims. ssRNA40 — routinely sold as a TLR7/8 ligand, and first reported as an activator of murine TLR7 and human TLR8 — produced nothing at all in a human TLR7 reporter line across 0.02–2000 nM, a 10⁵-fold range (see Wang2006 - Flavivirus Activation of pDCs and TLR7 Signaling). A compound marketed against a receptor pair may engage neither, one, or both, at doses that vary by orders of magnitude between them.

TRAF5, TLR9, DN2 B Cell, Age-Associated B Cell, Atypical B Cell, Activated Naive B Cell, Plasmablast, Extrafollicular Response, Toll-like Receptor Signaling in B Cells, ZEB2, T-bet, CD11c, IL-21, IFN-gamma, Inflammatory Monocyte, Plasmacytoid Dendritic Cell, Type I Interferon, SNP Genotyping, TLR Reporter Cell Assay, GC-Independent Response

Sources

Graph View

Backlinks